Indoximod

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Indoximod
DrugBank Accession Number
DB12827
Background

Indoximod has been used in trials studying the treatment of Glioma, Melanoma, Ependymoma, Gliosarcoma, and Lung Cancer, among others.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 218.256
Monoisotopic: 218.105527699
Chemical Formula
C12H14N2O2
Synonyms
  • (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid
  • 1-methyl-D-tryptophan
  • D-(+)-1-methyltryptophan
  • D-1-methyltryptophan
  • D-1MT
  • Indoximod

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as indolyl carboxylic acids and derivatives. These are compounds containing a carboxylic acid chain (of at least 2 carbon atoms) linked to an indole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolyl carboxylic acids and derivatives
Direct Parent
Indolyl carboxylic acids and derivatives
Alternative Parents
3-alkylindoles / D-alpha-amino acids / N-alkylindoles / Aralkylamines / Benzenoids / N-methylpyrroles / Heteroaromatic compounds / Amino acids / Carboxylic acids / Azacyclic compounds
show 6 more
Substituents
3-alkylindole / Alpha-amino acid / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
TX5CYN1KMZ
CAS number
110117-83-4
InChI Key
ZADWXFSZEAPBJS-SNVBAGLBSA-N
InChI
InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)/t10-/m1/s1
IUPAC Name
(2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid
SMILES
CN1C=C(C[C@@H](N)C(O)=O)C2=CC=CC=C12

References

General References
Not Available
PubChem Compound
405012
PubChem Substance
347828994
ChemSpider
358642
BindingDB
50207089
ChEMBL
CHEMBL571209
ZINC
ZINC000000039102
Wikipedia
1-Methyltryptophan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentMetastatic Breast Cancer1
2CompletedTreatmentMetastatic Prostate Cancer1
2RecruitingTreatmentDiffuse Intrinsic Pontine Gliomas (DIPG) / Ependymoma / High Grade Glioma: Glioblastoma (GBM) / Medulloblastomas1
2TerminatedTreatmentMelanoma1
1CompletedTreatmentAcute Myeloid Leukemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.721 mg/mLALOGPS
logP-0.82ALOGPS
logP-0.86Chemaxon
logS-2.5ALOGPS
pKa (Strongest Acidic)2.58Chemaxon
pKa (Strongest Basic)9.39Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area68.25 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity61.1 m3·mol-1Chemaxon
Polarizability23.37 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-00ec-4920000000-62f58350bd0fdb7d3a4e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0gb9-0090000000-7214c959965c0564f0d3
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-01b9-5390000000-b7523b269ca9feb7950d
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0avi-0940000000-21b07ebd2befd7605a64
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-9710000000-9062b912c8be1bc46bb5
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0zgi-0900000000-2f1bd3a67188aa7f7949
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0fc0-0900000000-0ba0d13c4e3ff8809995
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-148.38835
predicted
DeepCCS 1.0 (2019)
[M+H]+150.7839
predicted
DeepCCS 1.0 (2019)
[M+Na]+156.69643
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2016 00:32 / Updated at January 14, 2023 19:02